Table 1:
Active immunotherapy trials including patients with chordoma
| Trial Registration Number | Study Title | Type/Phase | Agent/Intervention |
|---|---|---|---|
| NCT02383498 | A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma | Phase II | Biological: GI-6301 Vaccine (Yeast- Brachyury) Other: GI-6301 Placebo Radiation: Radiotherapy |
| NCT03595228 | A Phase 2 Trial of BN-Brachyury and Radiation Therapy in Patients With Advanced Chordoma | Phase II | Biological: BN-Brachyury (brachyury vaccine) plus radiation |
| NCT03623854 | A Signal Finding Phase 2 Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) and Relatlimab (Anti-LAG-3 Monoclonal Antibody; BMS-986016) in Patients With Advanced Chordoma | Phase II | Biological: Nivolumab (anti-PD-1) Biological: Relatlimab (anti-LAG-3) |
| NCT02989636 | Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma | Phase I | Biological: Nivolumab (anti-PD-1) Radiation: Stereotactic Radiosurgery |
| NCT02601950 | A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | Phase II | Drug: Tazemetostat (for chordomas with SMARCB1/INI1 loss) |
| NCT02601937 | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Phase I | Drug: Tazemetostat (for chordomas with INI1 loss) |
| NCT02193503 | An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy | Phase I | Other: MVX-ONCO-1 (autologous tumor cell vaccine+ GM-CSF) |
| NCT03349983 | An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury) | Phase I | Biological: MVA-BN-Brachyury/FPV-Brachyury (Brachyury vaccine) |
| NCT03886311 | The TNT Protocol: A Phase 2 Study Using Talimogene Laherparepvec,Nivolumab and Trabectedin as First, Second/Third Line Therapy for Advanced Sarcoma, Including Desmoid Tumor and Chordoma | Phase II | Biological: Talimogene Laherparepvec [IMLYGIC] (oncolytic virus) Biological: Nivolumab (anti-PD-1) Drug: Trabectedin (chemotherapy inhibiting DNA binding of a family of transcription factors) |
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | --- | Drug: Tazemetostat (for chordomas with SMARCA4/INI1 loss) |
| NCT03173950 | Phase II trial of the immune checkpoint inhibitor nivolumab in patients with select rare CNS cancers | Phase II | Biological: Nivolumab (anti-PD-1) |
| NCT02815995 | A phase II multi-arm study to test the efficacy of immunotherapeutic agents in multiple sarcoma subtypes | Phase II | Biological: Durvalumab (anti-PD-1) Biological: Tremelimumab (anti-CTLA4) |